Wulandari Bangun Laksana Tbk (BSBK)

Overview

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative cancer therapeutics. Founded in 2012, the company is committed to improving the lives of patients battling cancer. With its headquarters in Shelton, Connecticut, Intensity Therapeutics is at the forefront of creating new paradigms in cancer treatment, aiming to address unmet medical needs and enhance patient outcomes across various cancer types. By advancing its proprietary drug candidates through clinical trials, the company endeavors to deliver safer, more effective cancer therapies to the market.

Products and Services

• INT230-6:

INT230-6 is Intensity Therapeutics’ leading product candidate, currently undergoing rigorous clinical testing for its efficacy and safety in treating several types of refractory solid tumors. This investigational drug is designed to target and destroy cancer cells while minimizing harm to healthy tissue, thus redefining cancer care with a novel approach. Key ongoing studies include:

• Phase 3 Clinical Trials for Soft Tissue Sarcoma: INT230-6 is being evaluated in advanced-stage clinical trials to determine its effectiveness in patients with soft tissue sarcoma, a type of cancer that affects the connective tissues of the body.
• Phase 2 Clinical Trials for Neoadjuvant and Metastatic Triple Negative Breast Cancer: INT230-6 is also in phase 2 clinical trials to assess its therapeutic potential in treating neoadjuvant and metastatic triple negative breast cancer, an aggressive form of the disease with limited treatment options.